section name header

Pronunciation ⬇

roe-PIN-i-role

Classifications ⬆ ⬇

Therapeutic Classification: antiparkinson agents

Pharmacologic Classification: dopamine agonists

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Stimulates dopamine receptors in the brain.
Therapeutic effects:
  • Decreased tremor and rigidity in Parkinson’s disease.
  • Decreased leg restlessness.

Pharmacokinetics ⬆ ⬇

Absorption: 55% absorbed following oral administration.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Extensively metabolized by the liver primarily by the CYP1A2 isoenzyme; <10% excreted unchanged in urine.

Half-Life: 6 hr.

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
POunknownunknown8 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: orthostatic hypotension, hypertension, peripheral edema, syncope

Derm: sweating

EENT: abnormal vision

GI: constipation, dry mouth, dyspepsia, nausea, vomiting

Neuro: dizziness, syncope, aggression, agitation, confusion, delirium, delusions, disorientation, drowsiness, dyskinesia, fatigue, hallucinations, headache, impulse control disorders (gambling, sexual, uncontrolled spending, binge/compulsive eating), insomnia, paranoid ideation, psychosis, SLEEP ATTACKS, somnolence, weakness

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Parkinson's Disease

Renal Impairment

Restless Leg Syndrome

Renal Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Requip, Requip XL

Code ⬆

NDC Code